Recruitment of STATs by KIT mutants

Stable Identifier
R-HSA-9670416
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Extracellular- , juxtamembrane- and kinase-domain mutants of KIT have been shown to signal through the STAT pathway, although the biological relevance or each STAT isoform varies between tumor types (Brizzi et al, 1999; Ning et al, 2001; Frost et al, 2002; Growney et al, 2005; Hara et al, 2017; Obata et al, 2017; Duensing et al, 2004; Bauer et al, 2007; Deberry et al, 1997; Ronnstrand, 2004). Although the pathway details haven't been examined in all cases, STAT pathway activation likely occurs through the recruitment of JAK2 and SRC family kinases, as is the case for the wild type receptor (reviewed in Lennartsson and Roonstrand, 2012).

Literature References
PubMed ID Title Journal Year
15007386 Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)

Duensing, A, Medeiros, F, McConarty, B, Joseph, NE, Panigrahy, D, Singer, S, Fletcher, CD, Demetri, GD, Fletcher, JA

Oncogene 2004
23073628 Stem cell factor receptor/c-Kit: from basic science to clinical implications

Lennartsson, J, Rönnstrand, L

Physiol. Rev. 2012
28192400 Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors

Obata, Y, Horikawa, K, Takahashi, T, Akieda, Y, Tsujimoto, M, Fletcher, JA, Esumi, H, Nishida, T, Abe, R

Oncogene 2017
28403213 M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells

Hara, Y, Obata, Y, Horikawa, K, Tasaki, Y, Suzuki, K, Murata, T, Shiina, I, Abe, R

PLoS ONE 2017
12481435 Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant

Frost, MJ, Ferrao, PT, Hughes, TP, Ashman, LK

Mol. Cancer Ther. 2002
10358045 STAT protein recruitment and activation in c-Kit deletion mutants

Brizzi, MF, Dentelli, P, Rosso, A, Yarden, Y, Pegoraro, L

J Biol Chem 1999
15526160 Signal transduction via the stem cell factor receptor/c-Kit

Rönnstrand, L

Cell Mol Life Sci 2004
9355737 Stat1 associates with c-kit and is activated in response to stem cell factor

DeBerry, C, Mou, S, Linnekin, D

Biochem J 1997
11369651 Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells

Ning, ZQ, Li, J, Arceci, RJ

Blood 2001
17546049 KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

Bauer, S, Duensing, A, Demetri, GD, Fletcher, JA

Oncogene 2007
15790786 Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Growney, JD, Clark, JJ, Adelsperger, J, Stone, R, Fabbro, D, Griffin, JD, Gilliland, DG

Blood 2005
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!